PDCD1 and non-small cell lung carcinoma: Several clinical studies have proved that immunotherapy, such as anti-programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) medicines, has proven efficacious in treating patients with advanced NSCLC [3].